Navigation Links
New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season
Date:5/20/2010

ST. PAUL, Minn., May 20 /PRNewswire/ -- Despite concerns from public health officials, influenza antiviral drugs were not hoarded during the recent H1N1 flu season, according to a new analysis presented recently at the Academy of Managed Care Pharmacy's 22nd Annual Meeting in San Diego by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.

For the study, researchers from Prime and one of its Blue Cross Blue Shield (BCBS) clients compared the use of influenza antiviral drugs during the H1N1 season to antiviral use during past flu seasons. The H1N1 global pandemic was declared in June 2009, and the U.S. Centers for Disease Control (CDC) recommended that patients at high risk of a complication, or those suspected of influenza and with more serious symptoms, receive antiviral medications. Amidst public concern about the pandemic, public health officials warned against hoarding of antiviral medication.

Researchers examined antiviral use among nine million members enrolled in commercial health plans across 11 states between September 2006 and December 2009 to determine the frequency of high-quantity and multiple-refill oseltamivir (a common influenza antiviral drug) claims among different geographic regions. While there was variability in antiviral use across geographic regions, use of antivirals during the H1N1 season was comparable to past flu seasons, and there was little indication of hoarding.

The study was designed to evaluate whether a utilization management program might increase patient safety and control costs. Researchers concluded that the impact of an antiviral quantity limit program would be limited given the low prevalence of high-quantity oseltamivir claims.

"During a pandemic, by monitoring the rate of prescriptions filled compared to past flu seasons, and watching for specific regional spikes in use that seem out of the ordinary, we can better determine whether medications are being hoarded," said Pat Gleason, PharmD, FCCP, BCPS, Director of Clinical Outcomes Assessment with Prime. "Preventing hoarding allows providers to better manage antiviral use to ensure those most in need are getting the medications. As we saw in this study, hoarding was not an issue during the recent H1N1 flu season."

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.7 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Greenway Medical Technologies PrimeSuite Wins Three Best in KLAS Awards
2. Greenway Medical Technologies PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification
3. Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards
4. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
5. Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
6. Osseon Therapeutics Demonstrates to the European Medical Community How to Think Outside The Balloon When Treating Vertebral Compression Fractures
7. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
8. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
9. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
10. Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
11. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... 18, 2019 , ... Uniform Advantage (UA), a leader in the ... Breast Cancer programs and services. , This year, more than 271,000 Americans will be ... the month of October 2019, Uniform Advantage will donate $5 for every unique use ...
(Date:9/17/2019)... , ... September 17, 2019 , ... Called Muss-Bits (Musical ... Company’s 2019 Innovation by Design Awards Students category. , It was developed by Associate ... Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor bit” that can ...
(Date:9/17/2019)... Mass. (PRWEB) , ... September 17, 2019 , ... ... long-term care industry, announces today the launch of RegistryConnect , the first ... input of registry owners. RegistryConnect includes care-matching, schedule recording, client and caregiver relationship ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... , ... Milwaukee-area dealership Hall Cars has hosted an annual event each fall for years in ... Out Cancer,” entails that for every vehicle purchased from Sept. 17 to Nov. 14, the ... 50 days, it has also been referred to as, “50 for 50.” , Though ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... Keflezighi and the American Heart Association (AHA)-San Diego Chapter to raise awareness of ... Stroke Walk on Saturday, September 21 in Balboa Park alongside National University System ...
(Date:9/17/2019)... ... September 17, 2019 , ... Encouraging a spirit of ... Cole, Vice President of Insurance Plan Management for Dental Care Alliance, the 2019 ... (NADP) at their annual conference, CONVERGE 2019, in Orlando. This award commends exemplary ...
(Date:9/17/2019)... SAN MATEO, Calif. (PRWEB) , ... September 17, ... ... under the CE Mark for Europe and the 21st Century Cures Act in ... on spine surgery, radiology, and pain management. Using images from existing MRI ...
(Date:9/17/2019)... Ga. (PRWEB) , ... September 17, 2019 , ... ... social responsibility initiative contributing to the long-term health of canines – specifically golden ... of all Golden Retrievers will die from cancer – one out of five ...
Breaking Medicine News(10 mins):